BioSpace News Archive

The global continuous renal replacement therapy (CRRT) market was valued at ~US$ 865 Mn in 2018. It is projected to expand at a high CAGR of ~7% from 2019 to 2027.

Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology.

New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma.

The global in-vitro cancer diagnostics market is expected to witness moderate growth during the forecast period between 2021 and 2031.

Portage Biotech Inc. today announced financial results for the fiscal quarter ended June 30, 2022.

Gradalis Inc. announced a peer-reviewed publication today in the Nature portfolio journal, Communications Medicine, in which several biomarkers were evaluated for their potential to predict survival following Vigil® (Gemogenovatucel-T) treatment.

TRACON Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical trial of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.

Aeterna Zentaris Inc. today announced that Novo Nordisk Healthcare AG (“Novo Nordisk”), has exercised its right to terminate the amended development and commercialization license agreement (the “CommericalLicense”) previously entered into between Aeterna’s wholly-owned subsidiary and Novo for Macrilen™ (macimorelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), today announced it has submitted a regulatory filing with the Department of Medical Equipment and Construction (“DMEC”) of Vietnam’s Ministry of Health for the ProSense System and accessories.

AIVITA Biomedical, Inc. today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel.